论文部分内容阅读
目的观察痰热清注射液治疗原发性肝癌介入化疗并栓塞治疗后不良反应的疗效。方法随机将32例原发性肝癌介入化疗并栓塞治疗后的患者分为两组,对照组16例,行常规极化液,护肝治疗;治疗组16例,在对照组的基础上加用痰热清。结果治疗组对不良反应的缓解情况,疗效显著率,显效率均优于对照组,差异有统计学意义(P<0.05)。治疗组在疗效显著率,显效率均优于对照组,差异有统计学意义(P<0.01)。治疗组在肝功能稳定方面优于对照组,差异有统计学意义(P<0.05)。结论痰热清注射液治疗原发性肝癌介入化疗并栓塞治疗后不良反应疗效显著。
Objective To observe the curative effect of Tanreqing injection in treating primary liver cancer after interventional chemotherapy and embolization. Methods Thirty-two patients with primary hepatocellular carcinoma (HCC) were randomly divided into two groups after interventional chemotherapy and embolization. Sixteen patients in the control group received conventional therapy and liver protection. In the treatment group, 16 patients were treated on the basis of the control group Tanreqing clear. Results The response rate of the treatment group to adverse reactions was significantly higher than that of the control group, with significant difference (P <0.05). The treatment group in the treatment of significant rate, significant efficiency were better than the control group, the difference was statistically significant (P <0.01). The treatment group was better than the control group in the stability of liver function, the difference was statistically significant (P <0.05). Conclusion Tanreqing injection in the treatment of primary liver cancer interventional chemotherapy and embolization after treatment of adverse reactions was significant.